ABL Bio

Beta

KRX Filings & Disclosures 2026

Management Discussion & Analysis

• • Revenue KRW 79.35B (+137.6% YoY), Operating loss KRW 40.39B (-32.0%), Net loss KRW 37.88B (-31.8%) in fiscal 2025
• • License-out business drove revenue increase by KRW 4.59B, led by upfront payments from GSK (GBP 38.5M) and milestone recognition from Sanofi (USD 75M)

Risk Factors

• • KRW 59.17B USD-denominated foreign currency assets and KRW 4.67B liabilities at FY2025-end
• • KRW 9.69B pre-tax loss impact from 10% KRW depreciation against foreign currencies at FY2025-end

Business Overview

• • KRW 79.35B revenue in FY2025 entirely from license-out of bispecific antibody, ADC, neurodegenerative treatments
• • Grabody-B BBB shuttle platform licensed to GSK (Apr 2025) and Eli Lilly (Nov 2025) for global exclusive rights, total contracts USD 2.64B upfronts

What are the latest ABL Bio DART filings in 2026?

ABL Bio (KRX code 298380) has filed an annual report on March 12, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did ABL Bio file its most recent annual report?

ABL Bio filed its most recent annual report on March 12, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is ABL Bio's KRX stock code?

ABL Bio's KRX stock code is 298380. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 298380 to look up all ABL Bio disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does ABL Bio file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for ABL Bio.

Where can I find ABL Bio financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from ABL Bio annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.